NH130
NH130 is a highly selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NH130 is a highly selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis. It is taken orally. The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours.
NH130 is under development by Jiangsu Nhwa Pharmaceutical in China. As of November 2025, it is in phase 2 clinical trials.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372023865 under CC BY-SA 4.0; modifications have been made.